|
Dec 6
|
Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea
|
|
Nov 29
|
Incannex Healthcare Announces Completion of its Redomiciliation to the United States
|
|
Jul 21
|
Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea
|
|
Jul 18
|
Incannex appoints CRO ahead of Phase 2/3 sleep apnoea trial
|
|
Jul 18
|
Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea
|
|
Apr 25
|
PharmAla Biotech to supply Incannex with GMP LaNeo MDMA and Psilocybin
|